Learn more about how you can help build a more equitable system for all
This study exposes the profound impact of extended patent protection that limits biosimilar competition and maintains high drug prices for patients and payers. The study highlights the staggering $158 billion in revenue amassed by drugmakers after the expiration of primary patent protection from just four biologic drugs: Humira, Avastin, Rituxan, and Lantus.